Abstract
Thrombocytopenia is seen commonly in patients with rheumatic disorders. In general, thrombocytopenia is due to one of three mechanisms: reduced production, sequestration, or increased platelet destruction. In outpatients, the most common cause of thrombocytopenia is immune thrombocytopenia. Immune thrombocytopenia encompasses a broad group of disorders in which the rate of immune-mediated platelet destruction surpasses the rate of platelet production. This paper discusses the diagnosis of immune thrombocytopenia, its mechanisms, and potential therapies for this problem. Acute therapy is with corticosteroids and intravenous immunoglobulin. Splenectomy is used if these fail. There also are other second-line therapies for treatment of patients with refractory thrombocytopenia. Potential toxicities of therapy are reviewed within the context of patients with rheumatic disorders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.